Multiple sclerosis : clinical and laboratory research
-
Neurofilament light chain (NfL) levels in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients correlate with the degree of neuronal injury. To date, little is known about NfL concentrations in the serum of relapsing remitting multiple sclerosis (RRMS) patients and their relationship with CSF levels and magnetic resonance imaging (MRI) measures of disease severity. We aimed to validate the quantification of NfL in serum samples of RRMS, as a biofluid source easily accessible for longitudinal studies. ⋯ CSF and serum NfL levels were highly correlated, and serum concentrations were increased in RRMS. Serum NfL levels correlated with MRI markers of WM disease severity. Our findings further support longitudinal studies of serum NfL as a potential biomarker of on-going disease progression and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.
-
To evaluate clinical fluid-attenuated inversion recovery (FLAIR)* 3T magnetic resonance imaging (MRI), which is sensitive to perivenular inflammatory demyelinating lesions, in diagnosing multiple sclerosis (MS). ⋯ Joint clinical evaluation of T2-FLAIR and FLAIR* images modestly improves diagnostic accuracy for MS and does not require counting lesions with central veins.
-
Corrigendum to 'Association of IL2RA polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA' Multiple Sclerosis Journal [Epub ahead of print] [DOI: 10.1177/1352458510394703].
-
Corrigendum to 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis by Trygve Holmøy, Stine Marit Moen, Thomas A Gundersen, Michael F Holick, Enrico Fainardi, Massimiliano Castellazzi and Ilaria Casetta. 15(11) 1280-1285 [DOI: 10.1177/1352458509107008].